Reprint

Targets, Tracers and Translation – Novel Radiopharmaceuticals Boost Nuclear Medicine

Edited by
September 2019
214 pages
  • ISBN978-3-03921-313-9 (Paperback)
  • ISBN978-3-03921-314-6 (PDF)

This book is a reprint of the Special Issue Targets, Tracers and Translation – Novel Radiopharmaceuticals Boost Nuclear Medicine that was published in

Biology & Life Sciences
Chemistry & Materials Science
Medicine & Pharmacology
Summary

This is the fourth Special Issue in Pharmaceuticals within the last six years dealing with aspects of radiopharmaceutical sciences. It demonstrates the significant interest and increasing relevance to ameliorate nuclear medicine imaging with PET or SPECT, and also radiotherapeutical procedures.Numerous targets and mechanisms have been identified and have been under investigation over the previous years, covering many fields of medical and clinical research. This development is well illustrated by the articles in the present issue, including 13 original research papers and one review, covering a broad range of actual research topics in the field of radiopharmaceutical sciences.

Format
  • Paperback
License
© 2019 by the authors; CC BY-NC-ND licence
Keywords
breast cancer; 68Ga; GRPR; NPY(Y1)R; peptide heterodimers; PET/CT imaging; sentinel lymph node; dextran; mannose; 99mTc-radiopharmaceuticals; glutamate; metabotropic glutamate receptor subtype 5; [18F]PSS232; ketamine; ceftriaxone; positron emission tomography; allosteric modulator; MMPEP; ABP688; pretargeting; Fusarinine C; rituximab; click chemistry; multimerization; PET; gallium-68; carbonic anhydrase IX; girentuximab; renal cell carcinomas; 177Lu-radiopharmaceuticals; radioimmunotherapy; neuroinflammation; microglia; carbon-11; radiochemistry; positron emission tomography; hypoxia; radiosensitizer; benzotriazine-1,4-dioxide (BTDO), benzotriazine-1-monoxide (BTMO), tirapazamine (TPZ), SR 4317; radioiodination; tropomyosin receptor kinase; positron emission tomography; neurodegeneration; oncogenic fusions; [11C]meta-hydroxyephedrine; radiosynthesis; separation; apparent molar activity; cholecystokinin-2 receptor; minigastrin; molecular imaging; radiometals; technetium-99m; hydrazinonicotinic acid (HYNIC); PSMA-617; salivary gland uptake; prostate cancer; endoradiotherapy; Chloramine T; electrophilic radioiodination; iodine-131; Iodo-Gen®; oxidizing agent; β-CIT.; tumor hypoxia; PET; small animal imaging; azomycin nucleosides; [18F]FMISO; bombesin; gastrin-releasing peptide; gastrin-releasing peptide receptor; tumor targeting; 99mTc-radioligand; metabolic stability; neprilysin-inhibition; phosphoramidon; n/a; n/a